Dendreon Presents Preclinical Data Demonstrating Activity Of Trp-p8 Agonist, D-3263, In Benign...

medicalnewstoday.com     May 22, 2008            

Researchers from Dendreon Corporation (Nasdaq: DNDN) presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets Trp-p8 (a transmembrane cation channel protein also known as Trp-M8), to treat benign prostatic hyperplasia (BPH). [read full story]                    

Full Coverage
                   

InPlay: Dendreon presents preclinical data demonstrating activity of Trp-p8 agonist, D-3263, in...

yahoo.com     May 21, 2008          

7:37AM Charming Shoppes beats by $0.07, misses on revs; guides Q2 EPS below consensus, revs below consensus 5.64 : Reports Q1 (Apr) earnings of $0.01 per share, $0.07 better than the First Call consensus of ($0.06); revenues fell 7.9% year/year to $641.3 mln vs the $725.2 mln consensus. Co issues...                    

comments

Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign...

yahoo.com     May 21, 2008          

Wednesday May 21, 7:30 am ET - News ) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets Trp-p8 (a transmembrane cation channel protein also known as Trp-M8), to treat benign prostatic hyperplasia (BPH). The...                    

comments

SmallCapReview.com: Small Caps to Watch - DNDN, ARMH, ANSV, SABA

tmcnet.com     May 21, 2008          

Dendreon Corporation (Nasdaq: DNDN) Closed at $5.37. In comparing untreated BPH-induced prostates to those treated with D-3263, treatment with D-3263 resulted in a 39 percent reduction in prostate weight compared to control (p=0.004). In addition, treatment with D-3263 resulted in a 98 percent...                    

comments

Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign...

prnewswire.com     May 21, 2008          

Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia - Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which...                    

comments

Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign...

drugs.com     May 22, 2008          

- Data Presented at American Urological Association Annual Meeting - SEATTLE and ORLANDO, Fla., May 21, 2008 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation today presented preclinical data demonstrating the potential of D-3263,... ... Data Presented at...                    

comments